Lafex 75mg Tablet ER contains Venlafaxine, an extended-release formulation indicated for the treatment of major depressive disorder, generalized anxiety disorder, social anxiety disorder, and panic disorder. Venlafaxine is a serotonin-norepinephrine reuptake inhibitor (SNRI) that functions by increasing the levels of neurotransmitters serotonin and norepinephrine in the brain, thereby improving mood and alleviating symptoms of depression and anxiety. The extended-release formulation allows for once-daily dosing, providing a steady release of the active ingredient over time, which enhances patient compliance and reduces the risk of side effects associated with peak plasma concentrations. Lafex 75mg Tablet ER should be administered orally, preferably with food to minimize gastrointestinal discomfort. Dosage adjustments may be necessary based on clinical response and tolerability, and gradual dose titration is recommended to reduce the risk of adverse effects such as nausea, dizziness, insomnia, and increased blood pressure. Patients should be monitored for worsening depression, suicidal ideation, or unusual changes in behavior, particularly during the initial treatment period or when doses are adjusted. Caution is advised in patients with hepatic or renal impairment, and abrupt discontinuation should be avoided to prevent withdrawal symptoms. Lafex 75mg Tablet ER should be used under the supervision of a qualified healthcare professional.